Aug 16, 2021 8:00am EDT SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Jul 29, 2021 8:00am EDT SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting
Jul 12, 2021 8:00am EDT SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID
Jul 07, 2021 8:30am EDT SCYNEXIS to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
Jun 23, 2021 8:30am EDT SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)
Jun 09, 2021 8:30am EDT SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
Jun 02, 2021 7:30am EDT SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections
